CSIMarket
 

Athersys Inc  (ATHX)

Athersys Inc's

Competitiveness




 

ATHX Sales vs. its Competitors Q3 2023



Comparing the current results to its competitors, Athersys Inc reported Revenue decrease in the 3 quarter 2023 year on year by 0 %, despite the revenue increase by the most of its competitors of 90.7 %, recorded in the same quarter.

List of ATHX Competitors





Revenue Growth Comparisons




Net Income Comparison


Athersys Inc recorded a net loss, as well as most of its competitors.

<<  ATHX Stock Performance Comparisons



*Market share is calculated based on total revenue.





Publicly Traded Peers of Athersys Inc




Hoth Therapeutics Inc
Share Performance



+7.28%
This Quarter



Hoth Therapeutics Inc
Profile

Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.

More about Hoth Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 19.537 mill. $ - mill. $ -13.321 mill.


Mesabi Trust
Share Performance



-3.73%
30 Days



Mesabi Trust
Profile

Mesabi Trust operates as a royalty trust, collecting royalty interest from leases of iron ore properties in Minnesota, United States. The trust receives revenue based on the mining and production of iron ore by others and distributes the collected amount to its unitholders on a quarterly basis. Essentially, Mesabi Trust's business model relies on generating income through the leasing and extraction of iron ore resources.

More about Mesabi Trust's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 294.282 mill. $ 92.981 mill. $ 85.892 mill.


Neurogene Inc
Share Performance



+24.96%
This Quarter



Neurogene Inc
Profile

The company develops genetic medicines targeting rare neurological diseases and is currently in clinical stages.

More about Neurogene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 811.873 mill. $ - mill. $ -111.110 mill.


Nkarta Inc
Share Performance



+49.24%
One Year



Nkarta Inc
Profile

Nkarta Inc is a biotechnology company with a business model centered on developing and commercializing engineered natural killer (NK) cell therapies for cancer patients. By utilizing proprietary technologies and expertise in genetic engineering, the company aims to enhance the therapeutic potential of NK cells and address unmet needs in the field of oncology. Nkarta Inc focuses on research, development, and production of these advanced cell therapies, collaborating with partners and regulators to bring innovative treatments to patients.

More about Nkarta Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 219.015 mill. $ - mill. $ -117.324 mill.


Nuvectis Pharma inc
Share Performance



+272.56%
One Year



Nuvectis Pharma inc
Profile

Nuvectis Pharma Inc's business model appears to focus on the development and commercialization of pharmaceutical products.

More about Nuvectis Pharma inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 538.774 mill. $ - mill. $ -30.275 mill.

76 more competitors available

Sign in to see all competitors

Sources: Athersys Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Athersys Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.